US FDA allows Synta to resume development of anticancer elesclomol
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals has received the go-ahead from the US FDA to resume development of its novel anticancer elesclomol, an oxidative stress inducer whose closely watched Phase III trial in metastatic melanoma was suspended last year on safety concerns.